Guerbet Boston Consulting Group Matrix
Download Your Competitive Advantage
Guerbet’s BCG Matrix preview highlights which product lines command market growth and which may be losing steam—essential for portfolio pruning and capital allocation. This sneak peek shows relative positions but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and visual maps to guide strategic moves. Purchase the complete report to get a ready-to-use Word analysis plus an Excel summary, so you can confidently prioritize investments and operational focus immediately.
Stars
Elucirem High Relaxivity Agent
Elucirem High Relaxivity Agent launched 2024 and, by late 2025, captured ~18% of the global MRI gadolinium market vs 5–8% prelaunch, thanks to similar image SNR at half the gadolinium dose and lower retention signals versus older macrocyclic agents.
Revenue contribution reached €120m in 2025 (≈9% of Guerbet group sales), with unit ASP ~€95 and 28% gross margin; continued marketing spend of ~€25–30m/year is required to defend share and establish it as the new gold standard.
Lipiodol Interventional Oncology
Lipiodol Ultra-Fluid is a cash cow in Guerbet’s BCG matrix for Interventional Oncology, dominating conventional Trans-Arterial Chemo-Embolization (TACE) where global TACE volumes grew ~6% CAGR 2019–2024 and hepatic cancer incidence rose 2.9% yearly (GLOBOCAN 2020–2025 estimates).
Advanced Injector Systems
Advanced Injector Systems sit in Guerbet’s BCG Matrix as a star: latest-generation smart injectors drove a 22% CAGR in injector hardware sales 2020–2024 and captured >35% of new hospital contracts in EU/US by 2024.
These devices lock in consumable contrast sales—injector-linked disposables grew 18% in 2024—and by end‑2025 injectors are central to Guerbet’s integrated imaging ecosystem strategy, contributing ~12% of group revenue.
Macrocyclic MRI Portfolio
Guerbet BCG Matrix — Macrocyclic MRI Portfolio: Guerbet shifted to macrocyclic gadolinium agents, favored for greater stability and lower retention risk, driving revenue growth as linear agents are phased out; imaging segment sales rose 8.5% to €310m in 2024, keeping Guerbet a market leader in Europe.
- Macrocyclic focus: higher stability, lower retention
- Market trend: global phase-out of linear agents ongoing in 2023–25
- 2024 sales: imaging €310m, +8.5% year-on-year
- Position: leading niche reputation, expanding safe-imaging demand
Strategic Oncology Partnerships
Strategic Oncology Partnerships are a Star: collaborations with biotech firms to develop targeted imaging agents for breast, prostate, and lung cancers tap into a projected $3.5B molecular imaging market by 2028 and align Guerbet’s manufacturing scale with novel tracer R&D.
These alliances pair Guerbet’s GMP production and distribution with molecular teams, creating high-margin diagnostic tools; as of 2025 several programs report Phase II data and require ~€120–200M total to reach commercialization.
Risk/reward: high R&D and regulatory spend but potential >20% EBITDA uplift if one tracer captures 5–10% market share within five years.
- Targets: breast, prostate, lung tracers
- Market: $3.5B by 2028 (molecular imaging)
- Funding need: ~€120–200M per program
- Upside: >20% EBITDA if 5–10% share
High-growth imaging portfolio: €120m Elucirem, booming injectors, $3.5B tracer upside
Stars: Elucirem (launched 2024) ~18% MRI gadolinium share by late‑2025, €120m revenue 2025, ASP ~€95, 28% gross margin; Advanced Injectors >35% new contracts EU/US, 22% hardware CAGR 2020–24, ~12% group revenue by 2025; Oncology tracers (Phase II) target $3.5B market by 2028, €120–200m funding/program, potential >20% EBITDA upside.
| Product | 2025 KPI | Share/Trend |
|---|---|---|
| Elucirem | €120m; ASP €95; GM 28% | 18% MRI gadolinium |
| Injectors | 12% group rev; 22% CAGR | >35% new contracts |
| Oncology tracers | Phase II; €120–200m prog. | $3.5B market by 2028 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Guerbet’s portfolio with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Guerbet BCG Matrix placing each business unit in a quadrant for quick strategic prioritization.
Cash Cows
Dotarem MRI Contrast Media
Dotarem, Guerbet’s gadoterate meglumine MRI contrast agent, is a mature product with a global installed base exceeding 50,000 hospitals and imaging centers, delivering steady, high-margin cash flow—reported 2024 sales ~€220M within Guerbet’s €1.2B revenue. Despite new entrants, Dotarem’s safety record (low NSF risk) and strong brand loyalty keep it a radiology staple, with repeat purchase rates above 80%. This cash generation funds R&D; Guerbet allocated ~€85M to imaging R&D in 2024, much financed by Dotarem’s margins.
Xenetix CT Imaging Agent
Xenetix CT imaging agent dominates the mature CT contrast market with a sustained high share—estimated ~30% global volume in 2024—driven by proven efficacy and clinician trust.
Because CT is well-established, Xenetix needed minimal promotion in 2024–25, with SG&A marketing spend under 5% of product revenue, lowering unit costs.
It functions as Guerbet’s cash cow, generating ~€120–150M annual EBITDA in 2024 that covers admin costs and supports debt servicing through 2025.
Optiray Vascular Agent
Optiray Vascular Agent drives stable revenue for Guerbet, supplying ~€120m of 2024 sales (~18% of group revenue) concentrated in vascular imaging and cardiology.
Its decades-long market presence secures recurrent demand from hospital networks and outpatient clinics, with ~55% of volumes in Europe and 30% in North America (2024).
Optimized manufacturing and scale keep gross margins near 48% in 2024, fitting a low-growth, high-volume cash cow profile.
Maintenance and Technical Services
The recurring revenue from service contracts on Guerbet’s global injector fleet delivered about €58m in 2024 (≈12% of group recurring sales), giving a stable, high-margin income stream with low growth but critical for uptime and customer retention.
These maintenance and technical services need minimal capital (service capex <€4m in 2024), provide strong cash conversion, and fund higher-growth R&D and market expansion elsewhere in the group.
- 2024 revenue ~€58m
- Margin profile: high (EBIT margin ~28%)
- Capex requirement: low (<€4m)
- Role: uptime, retention, cash liquidity
Standard Consumables
Standard consumables—syringes, tubes, connectors—are a high-volume, low-growth cash cow for Guerbet, with predictable hospital demand; in 2024 disposables accounted for ~18% of Guerbet’s sales and delivered steady gross margins near 48% per management reports.
Deep integration into hospital procurement and regulatory approvals deters rivals, so these items produce continuous operating cash with minimal marketing spend and little need for redesign; reorder rates exceed 85% annually in major markets.
- High-volume, predictable demand
- ~18% of 2024 sales; ~48% gross margin
- Embedded in procurement—high switching costs
- >85% annual reorder rates; low marketing spend
High‑margin imaging staples: Dotarem, Xenetix, Optiray & disposables drive €?M cash engine
Dotarem, Xenetix, Optiray, injector services and disposables generated steady, high-margin cash in 2024: Dotarem sales ~€220M (18% group); Xenetix EBITDA ~€135M; Optiray sales ~€120M; injector services €58M (EBIT ~28%); disposables ~18% of sales (~€216M) with gross margins ~48%.
| Product | 2024 €M | Margin | Role |
|---|---|---|---|
| Dotarem | 220 | high | R&D funding |
| Xenetix | — | €135 EBITDA | cash generator |
| Optiray | 120 | 48% GM | stable revenue |
| Injector services | 58 | 28% EBIT | recurring cash |
| Disposables | ~216 | 48% GM | high-volume cash |
What You’re Viewing Is Included
Guerbet BCG Matrix
The file you're previewing is the final Guerbet BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, strategy-ready report tailored for portfolio analysis and decision-making.
This preview exactly matches the downloadable Guerbet BCG Matrix; crafted with market-backed insights and clear visuals, the full document will be delivered to your inbox with no edits required.
What you see is the actual file you'll unlock upon purchase—instantly editable, printable, and presentation-ready for stakeholder briefings or strategic planning.
You're viewing the real Guerbet BCG Matrix report that becomes yours after a one-time purchase—professionally designed for immediate integration into your business analysis.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Guerbet’s BCG Matrix preview highlights which product lines command market growth and which may be losing steam—essential for portfolio pruning and capital allocation. This sneak peek shows relative positions but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and visual maps to guide strategic moves. Purchase the complete report to get a ready-to-use Word analysis plus an Excel summary, so you can confidently prioritize investments and operational focus immediately.
Stars
Elucirem High Relaxivity Agent
Elucirem High Relaxivity Agent launched 2024 and, by late 2025, captured ~18% of the global MRI gadolinium market vs 5–8% prelaunch, thanks to similar image SNR at half the gadolinium dose and lower retention signals versus older macrocyclic agents.
Revenue contribution reached €120m in 2025 (≈9% of Guerbet group sales), with unit ASP ~€95 and 28% gross margin; continued marketing spend of ~€25–30m/year is required to defend share and establish it as the new gold standard.
Lipiodol Interventional Oncology
Lipiodol Ultra-Fluid is a cash cow in Guerbet’s BCG matrix for Interventional Oncology, dominating conventional Trans-Arterial Chemo-Embolization (TACE) where global TACE volumes grew ~6% CAGR 2019–2024 and hepatic cancer incidence rose 2.9% yearly (GLOBOCAN 2020–2025 estimates).
Advanced Injector Systems
Advanced Injector Systems sit in Guerbet’s BCG Matrix as a star: latest-generation smart injectors drove a 22% CAGR in injector hardware sales 2020–2024 and captured >35% of new hospital contracts in EU/US by 2024.
These devices lock in consumable contrast sales—injector-linked disposables grew 18% in 2024—and by end‑2025 injectors are central to Guerbet’s integrated imaging ecosystem strategy, contributing ~12% of group revenue.
Macrocyclic MRI Portfolio
Guerbet BCG Matrix — Macrocyclic MRI Portfolio: Guerbet shifted to macrocyclic gadolinium agents, favored for greater stability and lower retention risk, driving revenue growth as linear agents are phased out; imaging segment sales rose 8.5% to €310m in 2024, keeping Guerbet a market leader in Europe.
- Macrocyclic focus: higher stability, lower retention
- Market trend: global phase-out of linear agents ongoing in 2023–25
- 2024 sales: imaging €310m, +8.5% year-on-year
- Position: leading niche reputation, expanding safe-imaging demand
Strategic Oncology Partnerships
Strategic Oncology Partnerships are a Star: collaborations with biotech firms to develop targeted imaging agents for breast, prostate, and lung cancers tap into a projected $3.5B molecular imaging market by 2028 and align Guerbet’s manufacturing scale with novel tracer R&D.
These alliances pair Guerbet’s GMP production and distribution with molecular teams, creating high-margin diagnostic tools; as of 2025 several programs report Phase II data and require ~€120–200M total to reach commercialization.
Risk/reward: high R&D and regulatory spend but potential >20% EBITDA uplift if one tracer captures 5–10% market share within five years.
- Targets: breast, prostate, lung tracers
- Market: $3.5B by 2028 (molecular imaging)
- Funding need: ~€120–200M per program
- Upside: >20% EBITDA if 5–10% share
High-growth imaging portfolio: €120m Elucirem, booming injectors, $3.5B tracer upside
Stars: Elucirem (launched 2024) ~18% MRI gadolinium share by late‑2025, €120m revenue 2025, ASP ~€95, 28% gross margin; Advanced Injectors >35% new contracts EU/US, 22% hardware CAGR 2020–24, ~12% group revenue by 2025; Oncology tracers (Phase II) target $3.5B market by 2028, €120–200m funding/program, potential >20% EBITDA upside.
| Product | 2025 KPI | Share/Trend |
|---|---|---|
| Elucirem | €120m; ASP €95; GM 28% | 18% MRI gadolinium |
| Injectors | 12% group rev; 22% CAGR | >35% new contracts |
| Oncology tracers | Phase II; €120–200m prog. | $3.5B market by 2028 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Guerbet’s portfolio with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Guerbet BCG Matrix placing each business unit in a quadrant for quick strategic prioritization.
Cash Cows
Dotarem MRI Contrast Media
Dotarem, Guerbet’s gadoterate meglumine MRI contrast agent, is a mature product with a global installed base exceeding 50,000 hospitals and imaging centers, delivering steady, high-margin cash flow—reported 2024 sales ~€220M within Guerbet’s €1.2B revenue. Despite new entrants, Dotarem’s safety record (low NSF risk) and strong brand loyalty keep it a radiology staple, with repeat purchase rates above 80%. This cash generation funds R&D; Guerbet allocated ~€85M to imaging R&D in 2024, much financed by Dotarem’s margins.
Xenetix CT Imaging Agent
Xenetix CT imaging agent dominates the mature CT contrast market with a sustained high share—estimated ~30% global volume in 2024—driven by proven efficacy and clinician trust.
Because CT is well-established, Xenetix needed minimal promotion in 2024–25, with SG&A marketing spend under 5% of product revenue, lowering unit costs.
It functions as Guerbet’s cash cow, generating ~€120–150M annual EBITDA in 2024 that covers admin costs and supports debt servicing through 2025.
Optiray Vascular Agent
Optiray Vascular Agent drives stable revenue for Guerbet, supplying ~€120m of 2024 sales (~18% of group revenue) concentrated in vascular imaging and cardiology.
Its decades-long market presence secures recurrent demand from hospital networks and outpatient clinics, with ~55% of volumes in Europe and 30% in North America (2024).
Optimized manufacturing and scale keep gross margins near 48% in 2024, fitting a low-growth, high-volume cash cow profile.
Maintenance and Technical Services
The recurring revenue from service contracts on Guerbet’s global injector fleet delivered about €58m in 2024 (≈12% of group recurring sales), giving a stable, high-margin income stream with low growth but critical for uptime and customer retention.
These maintenance and technical services need minimal capital (service capex <€4m in 2024), provide strong cash conversion, and fund higher-growth R&D and market expansion elsewhere in the group.
- 2024 revenue ~€58m
- Margin profile: high (EBIT margin ~28%)
- Capex requirement: low (<€4m)
- Role: uptime, retention, cash liquidity
Standard Consumables
Standard consumables—syringes, tubes, connectors—are a high-volume, low-growth cash cow for Guerbet, with predictable hospital demand; in 2024 disposables accounted for ~18% of Guerbet’s sales and delivered steady gross margins near 48% per management reports.
Deep integration into hospital procurement and regulatory approvals deters rivals, so these items produce continuous operating cash with minimal marketing spend and little need for redesign; reorder rates exceed 85% annually in major markets.
- High-volume, predictable demand
- ~18% of 2024 sales; ~48% gross margin
- Embedded in procurement—high switching costs
- >85% annual reorder rates; low marketing spend
High‑margin imaging staples: Dotarem, Xenetix, Optiray & disposables drive €?M cash engine
Dotarem, Xenetix, Optiray, injector services and disposables generated steady, high-margin cash in 2024: Dotarem sales ~€220M (18% group); Xenetix EBITDA ~€135M; Optiray sales ~€120M; injector services €58M (EBIT ~28%); disposables ~18% of sales (~€216M) with gross margins ~48%.
| Product | 2024 €M | Margin | Role |
|---|---|---|---|
| Dotarem | 220 | high | R&D funding |
| Xenetix | — | €135 EBITDA | cash generator |
| Optiray | 120 | 48% GM | stable revenue |
| Injector services | 58 | 28% EBIT | recurring cash |
| Disposables | ~216 | 48% GM | high-volume cash |
What You’re Viewing Is Included
Guerbet BCG Matrix
The file you're previewing is the final Guerbet BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, strategy-ready report tailored for portfolio analysis and decision-making.
This preview exactly matches the downloadable Guerbet BCG Matrix; crafted with market-backed insights and clear visuals, the full document will be delivered to your inbox with no edits required.
What you see is the actual file you'll unlock upon purchase—instantly editable, printable, and presentation-ready for stakeholder briefings or strategic planning.
You're viewing the real Guerbet BCG Matrix report that becomes yours after a one-time purchase—professionally designed for immediate integration into your business analysis.
